PUBLISHER: Grand View Research | PRODUCT CODE: 1362965
PUBLISHER: Grand View Research | PRODUCT CODE: 1362965
North America Bloodstream Infection Testing Market Size, Share & Trends Analysis Report By Product (Instruments, Reagents & Consumables), By Sample Type, By Technology, By End-user, By Region, And Segment Forecasts, 2023 - 2030
North America Bloodstream Infection Testing Market Growth & Trends:
The North America bloodstream infection testing market size is expected to reach USD 408.53 million by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 3.6% from 2023 to 2030. Increasing demand for advanced bloodstream infection testing methods, the introduction of culture-independent tests, and a rising number of CROs and forensic & research laboratories are among the major factors expected to drive growth in the bloodstream infection testing market.
Bloodstream infections (BSIs) are associated with adverse health-economic and clinical outcomes. A substantial portion (30-40%) of severe sepsis and septic shock cases can be attributed to culture-proven BSIs, which exhibit a sharp decline in survival rates if appropriate antimicrobial therapy is not administered within the first 24 hours. To mitigate this risk, clinicians often resort to broad-spectrum antimicrobial therapy without precise pathogen identification, leading to the selection and spread of resistant pathogens.
Implementing rapid BSI detection methods with antibiotic susceptibility testing can revolutionize infection control practices, therapeutic management, and clinical decision-making. This approach has the potential to reduce unnecessary antimicrobial prescriptions, lower the prevalence of adverse outcomes, and optimize resource utilization in healthcare settings.
The key players in the regional bloodstream infection testing market, such as F. Hoffmann-La Roche Ltd., bioMerieux SA, T2 Biosystems, BD, Cepheid, etc., are implementing strategic initiatives such as mergers, acquisitions, and collaborations to enhance product capabilities and promote their offerings. For instance, in June 2023, T2 Biosystems, Inc., a major provider of rapid sepsis detection solutions in the U.S., established a collaborative partnership with Vanderbilt University Medical Center's Learning Healthcare System (LHS) Platform.
As part of the collaboration, Vanderbilt University Medical Center will integrate and assess the FDA-cleared T2Bacteria Panel in a clinical setting. A prospective study will be conducted to evaluate the impact of utilizing the T2Bacteria Panel directly from blood samples, focusing on improving antibiotic usage and clinical interventions for patients diagnosed with bloodstream infections. This partnership indicates a significant step forward in advancing sepsis management and underscores both organizations' commitment to driving positive change in healthcare delivery.
North America Bloodstream Infection Testing Market Report Highlights:
- Based on the product, the reagents and consumables segment accounted for the largest revenue share owing to the easy availability and frequent purchase of screening products for donors and recipients
- Based on sample type, the blood culture segment dominated the market owing to the launch of automated blood culture systems and their improved efficacy
- Based on technology, the PCR segment held the largest revenue share in 2022 and is the most preferred technology among doctors and patients
- Hospital and diagnostic centers led the end-user segment in 2022, which is attributable to the increasing number of hospitalizations
- The U.S. dominated the North American bloodstream infection testing market in 2022 due to favorable reimbursement policies, the high prevalence of infections, and the presence of a large patient pool in the country
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
- 1.1.1.1. Sample Type segment
- 1.1.1.2. Product segment
- 1.1.1.3. Technology segment
- 1.1.1.4. End-user segment
- 1.1.1. Segment Definitions
- 1.2. Regional Scope
- 1.3. Estimates and Forecast Timeline
- 1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
- 1.5. Research Methodology
- 1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary research
- 1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
- 1.8. Market Formulation & Validation
- 1.9. Model Details
- 1.9.1. Commodity Flow Analysis
- 1.10. List of Secondary Sources
- 1.11. List of Abbreviations
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Product and Sample Type Snapshot
- 2.3. Technology and End-user Snapshot
- 2.4. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of infectious diseases
- 3.2.1.2. Technological Advancements in Bloodstream infection testing
- 3.2.1.3. Growing Initiatives for blood donations campaign
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Diagnosis Cost and Lower Investments in Underdeveloped Countries
- 3.2.1. Market Driver Analysis
- 3.3. Industry Analysis Tools
- 3.3.1. Porter's Five Forces Analysis
- 3.3.2. PESTEL Analysis
- 3.3.3. COVID-19 Impact Analysis
Chapter 4. North America Bloodstream Infection Testing Market: Product Business Analysis
- 4.1. North America Bloodstream Infection Testing Market: Product Movement Analysis
- 4.2. Instruments
- 4.2.1. Instruments Market, 2018 - 2030 (USD Million)
- 4.3. Reagents and Consumables
- 4.3.1. Reagents and Consumables Market, 2018 - 2030 (USD Million)
Chapter 5. North America Bloodstream Infection Testing Market: Sample Type Business Analysis
- 5.1. North America Bloodstream Infection Testing Market: Sample Type Movement Analysis
- 5.2. Whole Blood
- 5.2.1. Whole Blood Market, 2018 - 2030 (USD Million)
- 5.3. Blood Culture
- 5.3.1. Blood Culture Market, 2018 - 2030 (USD Million)
Chapter 6. North America Bloodstream Infection Testing Market: Technology Business Analysis
- 6.1. North America Bloodstream Infection Testing Market: Technology Movement Analysis
- 6.2. PCR
- 6.2.1. PCR Market, 2018 - 2030 (USD Million)
- 6.3. Mass Spectroscopy
- 6.3.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
- 6.4. In Situ Hybridization
- 6.4.1. In Situ Hybridization Market, 2018 - 2030 (USD Million)
- 6.5. Others
- 6.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 7. North America Bloodstream Infection Testing Market: End-User Business Analysis
- 7.1. North America Bloodstream Infection Testing Market: End-User Movement Analysis
- 7.2. Hospitals & Diagnostic Centers
- 7.2.1. Hospitals & Diagnostics Centers Market, 2018 - 2030 (USD Million)
- 7.3. Custom Laboratory Service Providers
- 7.3.1. Custom Laboratory Service Providers Market, 2018 - 2030 (USD Million)
- 7.4. Academic & Research Institutes
- 7.4.1. Academic & Research Institutes Market, 2018 - 2030 (USD Million)
- 7.5. Others
- 7.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 8. North America Bloodstream Infection Testing Market: Regional Business Analysis
- 8.1. North America
- 8.1.1. SWOT Analysis
- 8.1.2. North America Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
- 8.1.3. U.S.
- 8.1.3.1. Key Country Dynamics
- 8.1.3.2. Target Disease Prevalence
- 8.1.3.3. Competitive Scenario
- 8.1.3.4. Regulatory Framework
- 8.1.3.5. U.S. Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
- 8.1.4. Canada
- 8.1.4.1. Key Country Dynamics
- 8.1.4.2. Target Disease Prevalence
- 8.1.4.3. Competitive Scenario
- 8.1.4.4. Regulatory Framework
- 8.1.4.5. Canada Bloodstream Infection Testing Market, 2018 - 2030 (USD Million)
Chapter 9. North America Bloodstream Infection Testing Market: Competitive Landscape
- 9.1. Participant Categorization
- 9.1.1. bioMerieux SA
- 9.1.1.1. Overview
- 9.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.1.3. Product Benchmarking
- 9.1.1.4. Strategic Initiatives
- 9.1.2. BD
- 9.1.2.1. Overview
- 9.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.2.3. Product Benchmarking
- 9.1.2.4. Strategic Initiatives
- 9.1.3. Cepheid
- 9.1.3.1. Overview
- 9.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.3.3. Product Benchmarking
- 9.1.3.4. Strategic Initiatives
- 9.1.4. Seegene Inc.
- 9.1.4.1. Overview
- 9.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.4.3. Product Benchmarking
- 9.1.4.4. Strategic Initiatives
- 9.1.5. Abbott
- 9.1.5.1. Overview
- 9.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.5.3. Product Benchmarking
- 9.1.5.4. Strategic Initiatives
- 9.1.6. F. Hoffmann-La Roche Ltd
- 9.1.6.1. Overview
- 9.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.6.3. Product Benchmarking
- 9.1.6.4. Strategic Initiatives
- 9.1.7. Siemens Healthcare Limited
- 9.1.7.1. Overview
- 9.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.7.3. Product Benchmarking
- 9.1.7.4. Strategic Initiatives
- 9.1.8. Luminex Corporation
- 9.1.8.1. Overview
- 9.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.8.3. Product Benchmarking
- 9.1.8.4. Strategic Initiatives
- 9.1.9. Bruker
- 9.1.9.1. Overview
- 9.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.9.3. Product Benchmarking
- 9.1.9.4. Strategic Initiatives
- 9.1.10. Accelerate Diagnostics, Inc.
- 9.1.10.1. Overview
- 9.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
- 9.1.10.3. Product Benchmarking
- 9.1.10.4. Strategic Initiatives
- 9.1.1. bioMerieux SA
- 9.2. Participant's Overview
- 9.3. Financial Performance
- 9.4. Product Benchmarking
- 9.5. Company Market Share Analysis, 2022
- 9.6. Strategy Mapping
- 9.6.1. Expansion
- 9.6.2. Acquisition
- 9.6.3. Product/Service Launch
- 9.6.4. Others
Chapter 10. Analyst View
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviations
- Table 3 North America Bloodstream Infection Testing Market, By Country, 2018 - 2030 (USD Million)
- Table 4 North America Bloodstream Infection Testing Market, By Product, 2018 - 2030 (USD Million)
- Table 5 North America Bloodstream Infection Testing Market, By Sample Type, 2018 - 2030 (USD Million)
- Table 6 North America Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
- Table 7 North America Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)
- Table 8 U.S. Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
- Table 9 U.S. Bloodstream Infection Testing market, by Sample Type, 2018 - 2030 (USD Million)
- Table 10 U.S. Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
- Table 11 U.S. Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)
- Table 12 Canada Bloodstream Infection Testing market, by Product, 2018 - 2030 (USD Million)
- Table 13 Canada Bloodstream Infection Testing market, by Sample Type, 2018 - 2030 (USD Million)
- Table 14 Canada Bloodstream Infection Testing Market, By Technology, 2018 - 2030 (USD Million)
- Table 15 Canada Bloodstream Infection Testing market, by End-user, 2018 - 2030 (USD Million)
List of Figures
- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 Value chain-based sizing & forecasting
- Fig. 6 Market formulation & validation
- Fig. 7 Microscope software, market segmentation
- Fig. 8 Market snapshot, 2022
- Fig. 9 Market Trends & Outlook
- Fig. 10 Market driver relevance analysis (current & future impact)
- Fig. 11 Market restraint relevance analysis (current & future impact)
- Fig. 12 Market challenge relevance analysis (current & future impact)
- Fig. 13 SWOT analysis
- Fig. 14 Porter's five forces analysis
- Fig. 15 Regional marketplace: key takeaways
- Fig. 16 Regional outlook, 2022 & 2030
- Fig. 17 North America bloodstream infection testing market: region movement analysis.
- Fig. 18 North America bloodstream infection testing market, 2018 - 2030 (USD Million)
- Fig. 19 U.S. key country dynamics
- Fig. 20 U.S. bloodstream infection testing market, 2018 - 2030 (USD Million)
- Fig. 21 Canada key country dynamics
- Fig. 22 Canada bloodstream infection testing market, 2018 - 2030 (USD Million)
